362 related articles for article (PubMed ID: 9593264)
21. [Clinical Significance of Minimal Residual Disease in Pediatric Patients with
Xue YJ; Lu AD; Wang Y; Jia YP; Zuo YX; Zhang LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1303-1308. PubMed ID: 37846676
[TBL] [Abstract][Full Text] [Related]
22. Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia.
Uckun FM; Stork L; Seibel N; Sarquis M; Bedros C; Sather H; Sensel M; Reaman GH; Gaynon PS
Clin Cancer Res; 2000 Aug; 6(8):3123-30. PubMed ID: 10955793
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse.
Coustan-Smith E; Gajjar A; Hijiya N; Razzouk BI; Ribeiro RC; Rivera GK; Rubnitz JE; Sandlund JT; Andreansky M; Hancock ML; Pui CH; Campana D
Leukemia; 2004 Mar; 18(3):499-504. PubMed ID: 14981525
[TBL] [Abstract][Full Text] [Related]
24. Minimal residual disease in childhood acute lymphoblastic leukemia: analysis of patients in continuous complete remission or with consecutive relapse.
Biondi A; Yokota S; Hansen-Hagge TE; Rossi V; Giudici G; Maglia O; Basso G; Tell C; Masera G; Bartram CR
Leukemia; 1992 Apr; 6(4):282-8. PubMed ID: 1316978
[TBL] [Abstract][Full Text] [Related]
25. In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia.
Lönnerholm G; Thörn I; Sundström C; Frost BM; Abrahamsson J; Behrendtz M; Heldrup J; Jacobsson S; Li A; Olofsson T; Porwit A; Söderhäll S; Larsson R; Forestier E
Leuk Res; 2009 Jan; 33(1):46-53. PubMed ID: 18639340
[TBL] [Abstract][Full Text] [Related]
26. [The clinical significance of detecting minimal residual disease in acute childhood B-cell lymphoblastic leukemia with flow cytometry].
Zhang LP; Cheng YF; Liu GL; Lu AD; Liu YR; Wang H
Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):481-5. PubMed ID: 16083543
[TBL] [Abstract][Full Text] [Related]
27. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
[TBL] [Abstract][Full Text] [Related]
28. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia.
Neale GA; Coustan-Smith E; Pan Q; Chen X; Gruhn B; Stow P; Behm FG; Pui CH; Campana D
Leukemia; 1999 Aug; 13(8):1221-6. PubMed ID: 10450750
[TBL] [Abstract][Full Text] [Related]
29. MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: outcome prediction strongly depends on the therapeutic regimen.
zur Stadt U; Harms DO; Schlüter S; Schrappe M; Goebel U; Spaar H; Janka G; Kabisch H
Leukemia; 2001 Feb; 15(2):283-5. PubMed ID: 11236947
[No Abstract] [Full Text] [Related]
30. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.
Van der Velden VH; Corral L; Valsecchi MG; Jansen MW; De Lorenzo P; Cazzaniga G; Panzer-Grümayer ER; Schrappe M; Schrauder A; Meyer C; Marschalek R; Nigro LL; Metzler M; Basso G; Mann G; Den Boer ML; Biondi A; Pieters R; Van Dongen JJ;
Leukemia; 2009 Jun; 23(6):1073-9. PubMed ID: 19212338
[TBL] [Abstract][Full Text] [Related]
32. Post-induction residual disease in translocation t(12;21)-positive childhood ALL.
Seyfarth J; Madsen HO; Nyvold C; Ryder LP; Clausen N; Jonmundsson GK; Wesenberg F; Schmiegelow K
Med Pediatr Oncol; 2003 Feb; 40(2):82-7. PubMed ID: 12461790
[TBL] [Abstract][Full Text] [Related]
33. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia.
Mortuza FY; Papaioannou M; Moreira IM; Coyle LA; Gameiro P; Gandini D; Prentice HG; Goldstone A; Hoffbrand AV; Foroni L
J Clin Oncol; 2002 Feb; 20(4):1094-104. PubMed ID: 11844835
[TBL] [Abstract][Full Text] [Related]
34. Minimal residual disease monitoring cannot fully replace bone marrow morphology in assessing disease status in pediatric acute lymphoblastic leukemia.
Rathe M; Preiss B; Marquart HV; Schmiegelow K; Wehner PS
APMIS; 2020 May; 128(5):414-419. PubMed ID: 32108963
[TBL] [Abstract][Full Text] [Related]
35. A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome.
Coustan-Smith E; Ribeiro RC; Stow P; Zhou Y; Pui CH; Rivera GK; Pedrosa F; Campana D
Blood; 2006 Jul; 108(1):97-102. PubMed ID: 16537802
[TBL] [Abstract][Full Text] [Related]
36. Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood.
Mussolin L; Pillon M; Conter V; Piglione M; Lo Nigro L; Pierani P; Micalizzi C; Buffardi S; Basso G; Zanesco L; Rosolen A
J Clin Oncol; 2007 Nov; 25(33):5254-61. PubMed ID: 18024872
[TBL] [Abstract][Full Text] [Related]
37. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.
Stow P; Key L; Chen X; Pan Q; Neale GA; Coustan-Smith E; Mullighan CG; Zhou Y; Pui CH; Campana D
Blood; 2010 Jun; 115(23):4657-63. PubMed ID: 20304809
[TBL] [Abstract][Full Text] [Related]
39. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia.
Wasserman R; Galili N; Ito Y; Silber JH; Reichard BA; Shane S; Womer RB; Lange B; Rovera G
J Clin Oncol; 1992 Dec; 10(12):1879-88. PubMed ID: 1453203
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of detection of monoclonality in remission marrow in acute lymphoblastic leukemia in childhood. Australian and New Zealand Children's Cancer Study Group.
Brisco MJ; Condon J; Hughes E; Neoh SH; Nicholson I; Sykes PJ; Tauro G; Ekert H; Waters K; Toogood I
Leukemia; 1993 Oct; 7(10):1514-20. PubMed ID: 8412313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
